Periodic Transaction Report | U.S. Office of Government Ethics; 5 C.F.R. part 2634 (Updated Jan. 2019)

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Connery, Joyce L

Board Member, Defense Nuclear Facilities Safety Board

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Connery, Joyce L [electronically signed on 04/30/2019 by Connery, Joyce L in Integrity.gov]

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Gilman, Joseph S, Certifying Official [electronically signed on 05/07/2019 by Gilman, Joseph S in Integrity.gov]

Other review conducted by

/s/ Gilman, Joseph S, Ethics Official [electronically signed on 05/06/2019 by Gilman, Joseph S in Integrity.gov]

U.S. Office of Government Ethics Certification

/s/ Granahan, Megan, Certifying Official [electronically signed on 06/27/2019 by Granahan, Megan in Integrity.gov]

Data Revised 05/06/2019

т					: _		_
- 1	ra	115	าส	(l	Ю) []	5

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	Aetna Inc	See Endnote	Sale	11/29/2018	Yes	\$15,001 - \$50,000
2	CVS Caremark Corp.	See Endnote	Exchange	11/29/2018	Yes	\$1,001 - \$15,000

Endnotes

PART	#	ENDNOTE
Transactions	1	Filer previously held stock in Aetna. On Nov. 28, 2019, Aetna merged with CVS. As a result of the merger, each share of Aetna stock was automatically cancelled and converted into two parts: (1) 0.8378 of a share of CVS stock; and (2) cash consideration of \$145.00. These transactions represent the disposition of the filer's previously held Aetna stock as a result of the merger.
Transactions	2	Filer previously held stock in Aetna. On Nov. 28, 2019, Aetna merged with CVS. As a result of the merger, each share of Aetna stock was automatically cancelled and converted into two parts: (1) 0.8378 of a share of CVS stock; and (2) cash consideration of \$145.00. These transactions represent the disposition of the filer's previously held Aetna stock as a result of the merger.

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

Title I of the Ethics in Government Act of 1978, as amended (the Act), 5 U.S.C. app. § 101 et seq., as amended by the Stop Trading on Congressional Knowledge Act of 2012 (Pub. L. 112-105) (STOCK Act), and 5 C.F.R. Part 2634 of the U.S. Office of Government Ethics regulations require the reporting of this information. The primary

use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with sections 105 and 402(b)(1) of the Act or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to another Federal agency, court or party in a court or Federal administrative proceeding when the Government is a party or in order to comply with a judge-issued subpoena; (4) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (5) to the National Archives and Records Administration or the General Services Administration in records management inspections; (6) to the Office of Management and Budget during legislative coordination on private relief legislation; (7) to the Department of Justice or in certain legal proceedings when the disclosing agency, an employee of the disclosing agency, or the United States is a party to litigation or has an interest in the litigation and the use of such records is deemed relevant and necessary to the litigation; (8) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another; (9) to a Member of Congress or a congressional office in response to an inquiry made on behalf of an individual who is the subject of the record; (10) to contractors and other non-Government when necessary to accomplish a function related to an OGE Government-wi